Gerald Holtmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2493454/publications.pdf

Version: 2024-02-01

288 papers

15,322 citations

65 h-index 22764 112 g-index

328 all docs

328 docs citations

times ranked

328

10018 citing authors

#	Article	IF	Citations
1	Functional Gastroduodenal Disorders. Gastroenterology, 2006, 130, 1466-1479.	0.6	1,740
2	Immune Activation in Patients With Irritable Bowel Syndrome. Gastroenterology, 2007, 132, 913-920.	0.6	561
3	Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis. American Journal of Clinical Nutrition, 2018, 107, 965-983.	2.2	408
4	AGA technical review: Evaluation of dyspepsia. Gastroenterology, 1998, 114, 582-595.	0.6	378
5	Pathophysiology of irritable bowel syndrome. The Lancet Gastroenterology and Hepatology, 2016, 1, 133-146.	3.7	358
6	The Ion Channel TRPA1 Is Required for Normal Mechanosensation and Is Modulated by Algesic Stimuli. Gastroenterology, 2009, 137, 2084-2095.e3.	0.6	232
7	A Placebo-Controlled Trial of Itopride in Functional Dyspepsia. New England Journal of Medicine, 2006, 354, 832-840.	13.9	228
8	Selective Role for TRPV4 Ion Channels in Visceral Sensory Pathways. Gastroenterology, 2008, 134, 2059-2069.	0.6	228
9	Functional dyspepsia. Nature Reviews Disease Primers, 2017, 3, 17081.	18.1	226
10	G-protein \hat{l}^2 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia 1 \hat{a}^{-} †. Gastroenterology, 2004, 126, 971-979.	0.6	225
11	Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology, 1999, 117, 11-16.	0.6	201
12	Prokinetics in Patients with Gastroparesis: A Systematic Analysis. Digestion, 1999, 60, 422-427.	1.2	199
13	Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Alimentary Pharmacology and Therapeutics, 1999, 13, 225-235.	1.9	197
14	Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Alimentary Pharmacology and Therapeutics, 2004, 19, 271-279.	1.9	175
15	Sensory neuro-immune interactions differ between Irritable Bowel Syndrome subtypes. Gut, 2013, 62, 1456-1465.	6.1	172
16	Autism-related dietary preferences mediate autism-gut microbiome associations. Cell, 2021, 184, 5916-5931.e17.	13.5	172
17	Asiaâ€Pacific consensus on the management of gastroesophageal reflux disease: Update. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 8-22.	1.4	156
18	The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complementary and Alternative Medicine, 2019, 19, 21.	3.7	153

#	Article	IF	CITATIONS
19	Small Bowel Homing T Cells Are Associated With Symptoms and Delayed Gastric Emptying in Functional Dyspepsia. American Journal of Gastroenterology, 2011, 106, 1089-1098.	0.2	149
20	Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients. Inflammatory Bowel Diseases, 2007, 13, 225-234.	0.9	146
21	Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut, 2016, 65, 1402-1415.	6.1	144
22	Dyspepsia and the microbiome: time to focus on the small intestine. Gut, 2017, 66, 1168-1169.	6.1	139
23	MR Colonography with Barium-based Fecal Tagging: Initial Clinical Experience. Radiology, 2002, 223, 248-254.	3.6	127
24	Functional Dyspepsia Is Associated With a Greater Symptomatic Response to Fat But Not Carbohydrate, Increased Fasting and Postprandial CCK, and Diminished PYY. American Journal of Gastroenterology, 2008, 103, 2613-2623.	0.2	124
25	Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Alimentary Pharmacology and Therapeutics, 1999, 13, 1419-1427.	1.9	122
26	Altered vagal and intestinal mechanosensory function in chronic unexplained dyspepsia. Gut, 1998, 42, 501-506.	6.1	116
27	Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview. Digestive Diseases, 2017, 35, 5-13.	0.8	115
28	Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Alimentary Pharmacology and Therapeutics, 2003, 18, 1099-1105.	1.9	112
29	Dyspepsia in healthy blood donors. Digestive Diseases and Sciences, 1994, 39, 1090-1098.	1.1	111
30	Real time high resolution magnetic resonance imaging for the assessment of gastric motility disorders. Gut, 2004, 53, 1256-1261.	6.1	108
31	A randomized placeboâ€controlled trial on the effects of Menthacarin, a proprietary peppermintâ€and carawayâ€oilâ€preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroenterology and Motility, 2017, 29, e13132.	1.6	107
32	Mood and Anxiety Disorders Precede Development of Functional Gastrointestinal Disorders in Patients but Not in the Population. Clinical Gastroenterology and Hepatology, 2017, 15, 1014-1020.e4.	2.4	106
33	Effects of Iberogast® on Proximal Gastric Volume, Antropyloroduodenal Motility and Gastric Emptying in Healthy Men. American Journal of Gastroenterology, 2007, 102, 1276-1283.	0.2	104
34	Antidepressants and inflammatory bowel disease: a systematic review. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 24.	0.6	103
35	Relationship Between Symptoms and Dietary Patterns in Patients With Functional Dyspepsia. Clinical Gastroenterology and Hepatology, 2009, 7, 317-322.	2.4	102
36	Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Digestive Diseases and Sciences, 2019, 64, 480-486.	1.1	102

#	Article	IF	Citations
37	Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. American Journal of Gastroenterology, 2020, 115, 190-201.	0.2	102
38	Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: a four nations study. American Journal of Gastroenterology, 2000, 95, 1439-1447.	0.2	101
39	A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2012, 6, 302-310.	0.6	99
40	Treatment of Functional Dyspepsia with a Herbal Preparation. Digestion, 2004, 69, 45-52.	1.2	95
41	Determinants of health-related quality of life in patients with chronic liver diseases. Clinical Gastroenterology and Hepatology, 2004, 2, 157-163.	2.4	95
42	Altered postprandial motility in chronic pancreatitis: Role of malabsorption. Gastroenterology, 1997, 112, 1624-1634.	0.6	90
43	Dyspepsia in consulters and non-consulters. European Journal of Gastroenterology and Hepatology, 1994, 6, 917-924.	0.8	89
44	Is there an association between hospital accreditation and patient satisfaction with hospital care? A survey of 37 000 patients treated by 73 hospitals. International Journal for Quality in Health Care, 2011, 23, 278-283.	0.9	89
45	Review article: associations between <i>Helicobacter pylori</i> and obesity - an ecological study. Alimentary Pharmacology and Therapeutics, 2014, 40, 24-31.	1.9	89
46	Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia. Alimentary Pharmacology and Therapeutics, 2005, 22, 357-363.	1.9	88
47	New algorithm for the treatment of gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2008, 27, 249-256.	1.9	87
48	MR Colonography Without Colonic Cleansing. American Journal of Roentgenology, 2001, 177, 823-827.	1.0	86
49	Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model. Pain, 2006, 123, 179-186.	2.0	85
50	Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis?. American Journal of Gastroenterology, 1997, 92, 954-9.	0.2	84
51	Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy?. Alimentary Pharmacology and Therapeutics, 2007, 25, 973-986.	1.9	82
52	A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Alimentary Pharmacology and Therapeutics, 2002, 16, 1641-1648.	1.9	81
53	Increased visceral sensitivity to capsaicin after DSS-induced colitis in mice: spinal cord c-Fos expression and behavior. American Journal of Physiology - Renal Physiology, 2007, 293, G749-G757.	1.6	80
54	Differences in gastric mechanosensory function after repeated ramp distensions in non-consulters with dyspepsia and healthy controls. Gut, 2000, 47, 332-336.	6.1	75

#	Article	IF	CITATIONS
55	Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2003, 18, 569-580.	1.9	73
56	Phytotherapy for functional dyspepsia: A review of the clinical evidence for the herbal preparation STW 5. Phytomedicine, 2006, 13, 114-121.	2.3	72
57	Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological status. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 916-923.	1.4	72
58	Influence of cigarette smoking on the human duodenal mucosa-associated microbiota. Microbiome, 2018, 6, 150.	4.9	72
59	A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2002, 16, 479-485.	1.9	71
60	A genetic association study of 5-HTT LPR and GN?3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterology and Motility, 2007, 19, 465-470.	1.6	71
61	Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency. Pancreatology, 2016, 16, 164-180.	0.5	71
62	Characterisation of the gastrointestinal mucosaâ€associated microbiota: a novel technique to prevent crossâ€contamination during endoscopic procedures. Alimentary Pharmacology and Therapeutics, 2016, 43, 1186-1196.	1.9	69
63	Systematic review with metaâ€analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 624-635.	1.9	69
64	Functional Dyspepsia. Drugs, 1993, 45, 918-930.	4.9	66
65	Symptom patterns in functional dyspepsia and irritable bowel syndrome: relationship to disturbances in gastric emptying and response to a nutrient challenge in consulters and non-consulters. Gut, 2004, 53, 1445-1451.	6.1	65
66	MR Colonography in Patients with Incomplete Conventional Colonoscopy. Radiology, 2005, 234, 452-459.	3.6	64
67	Are There Alterations of Neuroendocrine and Cellular Immune Responses to Nutrients in Women with Irritable Bowel Syndrome?. American Journal of Gastroenterology, 2004, 99, 703-710.	0.2	62
68	Population based study: atopy and autoimmune diseases are associated with functional dyspepsia and irritable bowel syndrome, independent of psychological distress. Alimentary Pharmacology and Therapeutics, 2019, 49, 546-555.	1.9	62
69	A prospective randomized experimental evaluation of three-dimensional imaging in laparoscopy. Gastrointestinal Endoscopy, 1996, 44, 262-267.	0.5	60
70	Long-Term Effects of Transient Chemically Induced Colitis on the Visceromotor Response to Mechanical Colorectal Distension. Digestive Diseases and Sciences, 2004, 49, 96-101.	1.1	60
71	Functional dyspepsia. Current Opinion in Gastroenterology, 2016, 32, 467-473.	1.0	59
72	Impaired small intestinal peristaltic reflexes and sensory thresholds are independent functional disturbances in patients with chronic unexplained dyspepsia. American Journal of Gastroenterology, 1996, 91, 485-91.	0.2	59

#	Article	IF	CITATIONS
73	Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology. Journal of Gastroenterology, 2015, 50, 601-613.	2.3	57
74	Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease. Seminars in Liver Disease, 2017, 37, 388-400.	1.8	55
75	Prevalence of Unexplained Upper Abdominal Symptoms in Patients with Migraine. Cephalalgia, 2006, 26, 506-510.	1.8	54
76	The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2008, 28, 475-483.	1.9	54
77	Differential effects of acute mental stress on interdigestive secretion of gastric acid, pancreatic enzymes, and gastroduodenal motility. Digestive Diseases and Sciences, 1989, 34, 1701-1707.	1.1	53
78	Association betweenH. pylori, duodenal mechanosensory thresholds, and small intestinal motility in chronic unexplained dyspepsia. Digestive Diseases and Sciences, 1996, 41, 1285-1291.	1.1	52
79	Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Seminars in Liver Disease, 2019, 39, 432-441.	1.8	52
80	Public Speaking Stress-Induced Neuroendocrine Responses and Circulating Immune Cell Redistribution in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2006, 101, 2300-2307.	0.2	51
81	Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia?. Neurogastroenterology and Motility, 2010, 22, 262-e79.	1.6	51
82	Mental stress and gastric acid secretion. Digestive Diseases and Sciences, 1990, 35, 998-1007.	1.1	49
83	Pancreatic enzymes in chronic pancreatitis. International Journal of Gastrointestinal Cancer, 1994, 15, 1-11.	0.4	49
84	Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework. American Journal of Gastroenterology, 2020, 115, 814-822.	0.2	48
85	Nonischemic Chest Pain Induced by Coronary Interventions. Circulation, 1998, 98, 2656-2658.	1.6	46
86	The Validity of a New Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for Evaluating Symptoms in the Clinical Setting. Digestive Diseases and Sciences, 2017, 62, 1913-1922.	1.1	45
87	Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 128-140.	3.7	45
88	Does psychological status influence clinical outcomes in patients with inflammatory bowel disease (IBD) and other chronic gastroenterological diseases: An observational cohort prospective study. BioPsychoSocial Medicine, 2008, 2, 11.	0.9	44
89	Impairment of healthâ€related quality of life in functional dyspepsia and chronic liver disease: the influence of depression and anxiety. Alimentary Pharmacology and Therapeutics, 2008, 27, 561-571.	1.9	44
90	Unâ€promoted issues in inflammatory bowel disease: opportunities to optimize care. Internal Medicine Journal, 2010, 40, 173-182.	0.5	44

#	Article	IF	Citations
91	Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patients. Brain, Behavior, and Immunity, 2014, 42, 191-203.	2.0	44
92	Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. The Lancet Gastroenterology and Hepatology, 2022, 7, 17-27.	3.7	44
93	Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia. Alimentary Pharmacology and Therapeutics, 1999, 13, 1459-1465.	1.9	43
94	Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1137-1143.	1.4	43
95	Psychological problems in gastroenterology outpatients: A South Australian experience. Psychological co-morbidity in IBD, IBS and hepatitis C. Clinical Practice and Epidemiology in Mental Health, 2008, 4, 15.	0.6	43
96	Do changes in visceral sensory function determine the development of dyspepsia during treatment with aspirin?. Gastroenterology, 2002, 123, 1451-1458.	0.6	42
97	Anti-TNFÎ \pm therapy in IBD alters brain activity reflecting visceral sensory function and cognitive-affective biases. PLoS ONE, 2018, 13, e0193542.	1.1	42
98	1 Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: Clarifying the concepts. Bailliere's Clinical Gastroenterology, 1998, 12, 417-433.	0.9	41
99	Clinical Presentation and Personality Factors Are Predictors of the Response to Treatment in Patients with Functional Dyspepsia: A Randomized, Double-Blind Placebo-Controlled Crossover Study. Digestive Diseases and Sciences, 2004, 49, 672-679.	1.1	41
100	GERD 2003 – A Consensus on the Way Ahead. Digestion, 2003, 67, 111-117.	1.2	41
101	Challenging the holy grail of hospital accreditation: A cross sectional study of inpatient satisfaction in the field of cardiology. BMC Health Services Research, 2010, 10, 120.	0.9	40
102	The stomach–brain axis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 967-979.	1.0	40
103	Influence of Stress on the Healing and Relapse of Duodenal Ulcers: A Prospective, Multicenter Trial of 2109 Patients with Recurrent Duodenal Ulceration Treated with Ranitidine. Scandinavian Journal of Gastroenterology, 1992, 27, 917-923.	0.6	39
104	Antibody Response to Specific H. Pylori Antigens in Functional Dyspepsia, Duodenal Ulcer Disease, and Health. American Journal of Gastroenterology, 1998, 93, 1222-1227.	0.2	39
105	Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2004, 20, 47-56.	1.9	38
106	Mechanisms of Disease: genetics of functional gastrointestinal disordersâ€"searching the genes that matter. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 102-110.	1.7	38
107	Do We Know What Patients Want? The Doctor-Patient Communication Gap in Functional Gastrointestinal Disorders. Clinical Gastroenterology and Hepatology, 2009, 7, 1252-1254.e2.	2.4	38
108	Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: A systematic review and meta-analysis. Gut Microbes, 2021, 13, 1933313.	4.3	38

#	Article	IF	CITATIONS
109	Low ambient temperatures are associated with more rapid spread of COVID-19 in the early phase of the endemic. Environmental Research, 2020, 186, 109625.	3.7	38
110	A combination of peppermint oil and caraway oil attenuates the post-inflammatory visceral hyperalgesia in a rat model. Scandinavian Journal of Gastroenterology, 2006, 41, 155-160.	0.6	37
111	TRPV1-expressing sensory fibres and IBS: links with immune function. Gut, 2009, 58, 465-466.	6.1	37
112	Link Between Celiac Disease and Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2019, 53, 514-522.	1.1	37
113	Small Intestinal Bacterial Overgrowth in Functional Dyspepsia: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2021, 116, 935-942.	0.2	37
114	"It doesn't do any harm, but patients feel better": a qualitative exploratory study on gastroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease. BMC Gastroenterology, 2007, 7, 38.	0.8	36
115	Real-time high-resolution MRI for the assessment of gastric motility: Pre- and postpharmacological stimuli. Journal of Magnetic Resonance Imaging, 2004, 19, 453-458.	1.9	35
116	Effect of E. coli Nissle 1917 on post-inflammatory visceral sensory function in a rat model. Neurogastroenterology and Motility, 2005, 17, 410-414.	1.6	35
117	An Integrated Model of Care for Inflammatory Bowel Disease Sufferers in Australia: Development and the Effects of Its Implementation. Inflammatory Bowel Diseases, 2012, 18, 1573-1581.	0.9	35
118	Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics, 2005, 21, 11-20.	1.9	33
119	Hypothesis Driven Research and Molecular Mechanisms in Functional Dyspepsia: The Beginning of a Beautiful Friendship in Research and Practice?. American Journal of Gastroenterology, 2006, 101, 593-595.	0.2	33
120	Systematic review: healthâ€related quality of life (HRQOL) questionnaires in gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2008, 27, 1053-1070.	1.9	33
121	Adverse clinical phenotype in inflammatory bowel disease: A cross sectional study identifying factors potentially amenable to change. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1250-1258.	1.4	33
122	Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome. Clinical and Translational Gastroenterology, 2019, 10, e00064.	1.3	33
123	Review article: the patient with gastro-oesophageal reflux disease - lifestyle advice and medication. Alimentary Pharmacology and Therapeutics, 2004, 20, 24-27.	1.9	32
124	The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: A single metropolitan Australian center experience. Journal of Crohn's and Colitis, 2010, 4, 413-421.	0.6	32
125	Herbal Medicines for the Treatment of Functional and InflammatoryÂBowel Disorders. Clinical Gastroenterology and Hepatology, 2015, 13, 422-432.	2.4	32
126	Stress and gastrointestinal motility in animals: a review of the literature. Neurogastroenterology and Motility, 1992, 4, 83-90.	1.6	30

#	Article	IF	Citations
127	Stress and Gastrointestinal Motility in Humans: A Review of the Literature. Neurogastroenterology and Motility, 1991, 3, 245-254.	1.6	29
128	Effects of a fixed combination of peppermint oil and caraway oil on symptoms and quality of life in patients suffering from functional dyspepsia. Phytomedicine, 2003, 10, 56-57.	2.3	28
129	Psychological stress and the severity of post-inflammatory visceral hyperalgesia. European Journal of Pain, 2007, 11, 216-222.	1.4	28
130	Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 155-167.	1.9	28
131	Effect of transient chemically induced colitis on the visceromotor response to mechanical colorectal distension. European Journal of Gastroenterology and Hepatology, 2002, 14, 1067-1072.	0.8	27
132	Inconsistent symptom clusters for functional gastrointestinal disorders in Asia: is Rome burning?. Gut, 2018, 67, 1911-1915.	6.1	27
133	Capsaicin-Sensitive Nerve Fibres Induce Epithelial Cell Proliferation, Inflammatory Cell Immigration and Transforming Growth Factor-alpha Expression in the Rat Colonic Mucosa In Vivo. Scandinavian Journal of Gastroenterology, 2002, 37, 414-422.	0.6	26
134	Visceral pain and public speaking stress: Neuroendocrine and immune cell responses in healthy subjects. Brain, Behavior, and Immunity, 2006, 20, 49-56.	2.0	26
135	Management of Reflux Symptoms with Over-the-Counter Proton Pump Inhibitors: Issues and Proposed Guidelines. Digestion, 2009, 80, 226-234.	1.2	26
136	Incidence and prevalence of selfâ€reported nonâ€coeliac wheat sensitivity and gluten avoidance in Australia. Medical Journal of Australia, 2020, 212, 126-131.	0.8	26
137	Is there a causal link between psychological disorders and functional gastrointestinal disorders?. Expert Review of Gastroenterology and Hepatology, 2020, 14, 1047-1059.	1.4	26
138	Review article: From gastrin to gastro-oesophageal reflux disease - a century of acid suppression. Alimentary Pharmacology and Therapeutics, 2006, 23, 683-690.	1.9	25
139	Reflux disease: the disorder of the third millennium. European Journal of Gastroenterology and Hepatology, 2001, 13 Suppl 1, S5-11.	0.8	25
140	International validation of a healthâ€related quality of life questionnaire in patients with erosive gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2009, 29, 615-625.	1.9	24
141	The role of the microbiome and the use of probiotics in gastrointestinal disorders in adults in the Asiaâ€Pacific region ―background and recommendations of a regional consensus meeting. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 57-69.	1.4	24
142	Zonulin in serum as a biomarker fails to identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity. Gut, 2020, 69, 1719-1722.	6.1	24
143	Report of a Case With Giant Condyloma (Buschke-Lowenstein Tumor) Localized in the Bladder. Journal of Urology, 1995, 153, 1222-1224.	0.2	23
144	Survival of human pancreatic enzymes during small bowel transit: effect of nutrients, bile acids, and enzymes. American Journal of Physiology - Renal Physiology, 1997, 273, G553-G558.	1.6	23

#	Article	IF	Citations
145	Time-Resolved Three-Dimensional MR Imaging of Gastric Emptying Modified by IV Administration of Erythromycin. American Journal of Roentgenology, 2003, 180, 1305-1310.	1.0	23
146	Failed Therapy and Directions for the Future in Dyspepsia. Digestive Diseases, 2008, 26, 218-224.	0.8	23
147	Disturbed in vitro adrenergic modulation of cytokine production in inflammatory bowel diseases in remission. Journal of Neuroimmunology, 2007, 182, 195-203.	1.1	22
148	Clinical trial: the treatment of gastroâ€oesophageal reflux disease in primary care – prospective randomized comparison of rabeprazole 20â€∫mg with esomeprazole 20 and 40â€∫mg. Alimentary Pharmacology and Therapeutics, 2009, 29, 967-978.	1.9	22
149	Gastroduodenal "Dysbiosis― a New Clinical Entity. Current Treatment Options in Gastroenterology, 2018, 16, 591-604.	0.3	22
150	Duodenal Eosinophils and Mast Cells in Functional Dyspepsia: A Systematic Review and Meta-Analysis of Case-Control Studies. Clinical Gastroenterology and Hepatology, 2022, 20, 2229-2242.e29.	2.4	22
151	G protein-coupled receptor kinase 6 controls post-inflammatory visceral hyperalgesia. Brain, Behavior, and Immunity, 2009, 23, 18-26.	2.0	21
152	Proton-pump inhibitors or H2-receptor antagonists for Helicobacter pylori eradicationâ€"a meta-analysis. Lancet, The, 1996, 347, 763.	6.3	20
153	Epidemiological Trends of Functional Gastrointestinal Disorders. Digestive Diseases, 2001, 19, 189-194.	0.8	20
154	Diurnal variation of abdominal motor responses to colorectal distension and plasma cortisol levels in rats. Neurogastroenterology and Motility, 2001, 13, 585-589.	1.6	20
155	Non-physician endoscopists: A systematic review. World Journal of Gastroenterology, 2015, 21, 5056.	1.4	20
156	Perception of gastric distension. Digestive Diseases and Sciences, 1995, 40, 2673-2677.	1.1	19
157	Non-Erosive Reflux Disease – Defining the Entity and Delineating the Management. Digestion, 2008, 78, 1-5.	1.2	19
158	Recurrent Symptoms after Fundoplication with a Negative pH Studyâ€"Recurrent Reflux or Functional Heartburn?. Journal of Gastrointestinal Surgery, 2009, 13, 54-60.	0.9	19
159	Undiagnosed pancreatic exocrine insufficiency and chronic pancreatitis in functional GI disorder patients with diarrhea or abdominal pain. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1813-1817.	1.4	19
160	Ablation of connexin43 in smooth muscle cells of the mouse intestine: functional insights into physiology and morphology. Cell and Tissue Research, 2006, 327, 333-342.	1.5	18
161	Guideline adherence and patient satisfaction in the treatment of inflammatory bowel disorders – an evaluation study. BMC Health Services Research, 2009, 9, 17.	0.9	18
162	Functional dyspepsia. Current Opinion in Gastroenterology, 2015, Publish Ahead of Print, 492-8.	1.0	18

#	Article	IF	CITATIONS
163	The management of irritable bowel syndrome: a European, primary and secondary care collaboration. European Journal of Gastroenterology and Hepatology, 2001, 13, 933-939.	0.8	17
164	Molecular basis of functional gastrointestinal disorders. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 633-640.	1.0	17
165	Itopride in the Treatment of Functional Dyspepsia in Chinese Patients. Clinical Drug Investigation, 2011, 31, 865-875.	1.1	17
166	Basics of meta-analysis. Indian Journal of Gastroenterology, 2020, 39, 503-513.	0.7	16
167	Epigastric symptom response to low FODMAP dietary advice compared with standard dietetic advice in individuals with functional dyspepsia. Neurogastroenterology and Motility, 2021, 33, e14148.	1.6	16
168	Concomitant Irritable Bowel Syndrome Does Not Influence the Response to Antimicrobial Therapy in Patients with Functional Dyspepsia. Digestive Diseases and Sciences, 2022, 67, 2299-2309.	1.1	16
169	Transdiagnostic internet-delivered cognitive-behaviour therapy (CBT) for adults with functional gastrointestinal disorders (FGID): A feasibility open trial. Journal of Psychosomatic Research, 2018, 108, 61-69.	1.2	15
170	Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches. Digestive Diseases, 2020, 38, 269-279.	0.8	15
171	Psychogastroenterology: a call for psychological input in Australian gastroenterology clinics. Internal Medicine Journal, 2009, 39, 127-130.	0.5	14
172	Association between clinical manifestations of complicated and uncomplicated peptic ulcer and visceral sensory dysfunction. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1162-1169.	1.4	14
173	Host immune response determines visceral hyperalgesia in a rat model of post-inflammatory irritable bowel syndrome. Journal of Gastroenterology, 2013, 48, 1119-1127.	2.3	14
174	Is There a Link Between H. Pylori and the Epidemiology of Crohn's Disease?. Digestive Diseases and Sciences, 2017, 62, 2472-2480.	1.1	14
175	Influence of Simethicone Added to the Rinse Water during Colonoscopies on Polyp Detection Rates: Results of an Unintended Cohort Study. Digestion, 2018, 98, 217-221.	1.2	14
176	Platelet activating factor receptor acts to limit colitisâ€induced liver inflammation. FASEB Journal, 2020, 34, 7718-7732.	0.2	14
177	Letter: budesonide for functional dyspepsia with duodenal eosinophiliaâ€"randomised, doubleâ€blind, placeboâ€controlled parallelâ€group trial. Alimentary Pharmacology and Therapeutics, 2021, 53, 1332-1333.	1.9	14
178	Esophageal perforation, inflammatory mediastinitis and pseudoaneurysm of the thoracic aorta as potential complications of botulinum toxin injection for achalasia. Digestive Endoscopy, 2015, 27, 618-621.	1.3	13
179	Functional dyspepsia is associated with lower exercise levels: A populationâ€based study. United European Gastroenterology Journal, 2020, 8, 577-583.	1.6	13
180	Dysbiosis of the Duodenal Mucosal Microbiota Is Associated With Increased Small Intestinal Permeability in Chronic Liver Disease. Clinical and Translational Gastroenterology, 2019, 10, e00068.	1.3	13

#	Article	IF	CITATIONS
181	Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care for Functional Gastrointestinal Disorders (FGIDS): A Matched Cohort Study. Digestive Diseases and Sciences, 2022, 67, 5593-5601.	1.1	13
182	Gastrointestinal sensory function in functional dyspepsia. Gastroenterology, 1995, 109, 331.	0.6	12
183	Nutrients and cyclical interdigestive pancreatic enzyme secretion in humans Gut, 1996, 38, 920-924.	6.1	12
184	H. pylori and functional dyspepsia: increased serum antibodies as an independent risk factor?. Digestive Diseases and Sciences, 2001, 46, 1550-1557.	1.1	12
185	On-demand Treatment of Acute Heartburn With the Antacid Hydrotalcite Compared With Famotidine and Placebo. Journal of Clinical Gastroenterology, 2007, 41, 564-570.	1.1	12
186	GERD Evaluation. Journal of Clinical Gastroenterology, 2007, 41, 237-241.	1.1	12
187	Onset of relief of symptoms of gastroesophageal reflux disease: Post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily. Clinical Therapeutics, 2010, 32, 678-690.	1.1	12
188	"lt ain't over … till it's over!―Riskâ€mitigation strategies for patients with gastrointestinal diseases in the aftermath of the COVIDâ€19 pandemic. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1117-1123.	1.4	12
189	Defects in NLRP6, autophagy and goblet cell homeostasis are associated with reduced duodenal CRH receptor 2 expression in patients with functional dyspepsia. Brain, Behavior, and Immunity, 2022, 101, 335-345.	2.0	12
190	Histamine H2 receptor antagonists and blood alcohol levels. Digestive Diseases and Sciences, 1988, 33, 767-768.	1.1	11
191	Neuroendocrine and blood pressure responses to rectal distensions in individuals with high and low visceral pain sensitivity. Psychoneuroendocrinology, 2007, 32, 580-585.	1.3	11
192	Herbal medicines in functional dyspepsiaâ€"Untapped opportunities not without risks. Neurogastroenterology and Motility, 2021, 33, e14044.	1.6	11
193	Papillomatosis Confined to the Distal Biliary Tract ? A Rare Cause of Obstructive Jaundice: Report of a Case. Surgery Today, 2003, 33, 781-784.	0.7	10
194	IBS: A syndrome or many diseases?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 91-97.	1.0	10
195	Role of the duodenal microbiota in functional dyspepsia. Neurogastroenterology and Motility, 2022, 34, e14372.	1.6	10
196	Management of peptic ulcer bleeding-the roles of proton pump inhibitors and Helicobacter pylori eradication. Alimentary Pharmacology and Therapeutics, 2004, 19, 66-70.	1.9	9
197	Effects of neurokinins on human colonic motility. Neurogastroenterology and Motility, 1994, 6, 119-127.	1.6	9
198	Stress causes flares of IBDâ€"how much evidence is enough?. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 13-14.	8.2	9

#	Article	IF	Citations
199	Complicated and Uncomplicated Peptic Ulcer Disease: Altered Symptom Response to a Nutrient Challenge Linked to Gastric Motor Dysfunction. Digestion, 2014, 89, 239-246.	1.2	9
200	Liverâ€related mortality in countries of the developed world: an ecological study approach to explain the variability. Alimentary Pharmacology and Therapeutics, 2016, 44, 68-77.	1.9	9
201	Accuracy of polyp localization at colonoscopy. Endoscopy International Open, 2016, 04, E642-E646.	0.9	9
202	A Role for Primary Care Pharmacists in the Management of Inflammatory Bowel Disease? Lessons from Chronic Disease: A Systematic Review. Pharmacy (Basel, Switzerland), 2020, 8, 204.	0.6	9
203	Sleep disturbances in the irritable bowel syndrome and functional dyspepsia are independent of psychological distress: a populationâ€based study of 1322 Australians. Alimentary Pharmacology and Therapeutics, 2021, 54, 627-636.	1.9	9
204	Serum ferritin and survival of renal transplant recipients: a prospective 10-year cohort study. Transplant International, 2003, 16, 642-647.	0.8	8
205	Heartburn in primary care: problems below the surface. Journal of Gastroenterology, 2004, 39, 1027-1034.	2.3	8
206	Gastroesophageal reflux disease after diagnostic endoscopy in the clinical setting. World Journal of Gastroenterology, 2013, 19, 2514.	1.4	8
207	Overlap of heartburn, functional dyspepsia, and irritable bowel syndrome in a population sample: Prevalence, temporal stability, and associated comorbidities. Neurogastroenterology and Motility, 2022, 34, e14349.	1.6	8
208	Current and Future Approaches for Diagnosing Small Intestinal Dysbiosis in Patients With Symptoms of Functional Dyspepsia. Frontiers in Neuroscience, 2022, 16 , .	1.4	8
209	Epithelial cell-derived components induce transforming growth factor-α mRNA expression and epithelial cell proliferation in vitro. European Journal of Gastroenterology and Hepatology, 2001, 13, 1333-1340.	0.8	7
210	Improvement of Non-Steroidal Anti-Inflammatory Drug-Induced Gastrointestinal Symptoms during Proton Pump Inhibitor Treatment: Are G-Protein l^2 3 Subunit Genotype, Helicobacter pylori Status, and Environmental Factors Response Modifiers?. Digestion, 2011, 84, 289-298.	1.2	7
211	Clinical triage for colonoscopy is useful in young women. Internal Medicine Journal, 2015, 45, 492-496.	0.5	7
212	Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders. Wiener Medizinische Wochenschrift, 2018, 168, 89-98.	0.5	7
213	Irritable bowel syndrome and functional dyspepsia: what can epidemiology tell us about etiology?. Expert Review of Gastroenterology and Hepatology, 2018, 12, 633-635.	1.4	7
214	Clinical Conditions Associated With Bacterial Overgrowth. , 2019, , 67-83.		7
215	A novel treatment for patients with constipation: Dawn of a new age for translational microbiome research?. Indian Journal of Gastroenterology, 2018, 37, 388-391.	0.7	6
216	The use of modelling studies to inform planning of health services: case study of rapidly increasing endoscopy services in Australia. BMC Health Services Research, 2019, 19, 608.	0.9	6

#	Article	IF	CITATIONS
217	An Evidence-based Approach Towards Targeted Patient Education to Improve Bowel Preparation for Colonoscopy. Journal of Clinical Gastroenterology, 2020, 54, 707-713.	1.1	6
218	Utilising lipid and, arginine and proline metabolism in blood plasma to differentiate the biochemical expression in functional dyspepsia (FD) and irritable bowel syndrome (IBS). Metabolomics, 2022, 18, .	1.4	6
219	Telenzepine, a New M1-Receptor Antagonist, Is a More Potent Inhibitor of Pentagastrin-Stimulated Gastric Acid Output Than Pirenzepine in Dogs. Scandinavian Journal of Gastroenterology, 1990, 25, 293-297.	0.6	5
220	Potentially avoidable surgery in inflammatory bowel disease: what proportion of patients come to resection without optimal preoperative therapy? A guidelinesâ€based audit. Internal Medicine Journal, 2012, 42, e84-8.	0.5	5
221	Cost and time savings from a rapid access model of care using transient elastography to screen and triage patients with chronic Hepatitis C infection. Journal of Medical Economics, 2014, 17, 159-165.	1.0	5
222	Improving the Quality of Bowel Preparation: Rewarding Patients for Success or Intensive Patient Education?. Digestive Diseases, 2021, 39, 113-118.	0.8	5
223	Gastrointestinal problems in airline crew members. Zeitschrift Fur Gastroenterologie, 1995, 33, 513-6.	0.2	5
224	Links between celiac disease and small intestinal bacterial overgrowth: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1844-1852.	1.4	5
225	Does long-term maintenance therapy with ranitidine affect the natural course of duodenal ulcer disease?. European Journal of Gastroenterology and Hepatology, 1993, 5, 311-318.	0.8	4
226	Does doctors $\hat{E}\frac{1}{4}$ knowledge of inflammatory bowel disease patients $\hat{E}\frac{1}{4}$ psychological status affect patients $\hat{E}\frac{1}{4}$ clinical outcomes: a pilot randomized controlled trial. European Journal of Gastroenterology and Hepatology, 2009, 21, 484-485.	0.8	4
227	Patient Positioning Guidelines for Gastrointestinal Endoscopic Procedures. Gastroenterology Nursing, 2021, 44, 185-191.	0.2	4
228	Antibiotic use but not gastrointestinal infection frequently precedes first diagnosis of functional gastrointestinal disorders. United European Gastroenterology Journal, 2021, 9, 1074-1080.	1.6	4
229	Physician Perceptions on the Use of Antibiotics and Probiotics in Adults: An International Survey in the Asia-Pacific Area. Frontiers in Cellular and Infection Microbiology, 2021, 11, 722700.	1.8	4
230	Involvement of chloride channels in the receptormediated activation of longitudinal colonic muscle. Neurogastroenterology and Motility, 1998, 10, 489-498.	1.6	3
231	Intraoperative cholangioscopy in the management of biliary adenomas. Journal of Surgical Oncology, 2004, 85, 91-92.	0.8	3
232	Recombinant human erythropoietin counteracts cisplatin-induced visceral hyperalgesia. Neuroscience Bulletin, 2010, 26, 282-288.	1.5	3
233	Gut Inflammation: More Than a Peripheral Annoyance. Digestive Diseases and Sciences, 2017, 62, 2205-2207.	1.1	3
234	Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. American Journal of Gastroenterology, 2020, 115, 1007-1018.	0.2	3

#	Article	IF	Citations
235	Effects of a fixed peppermint oil caraway oil combination (PCC) on symptoms and quality of life in functional dyspepsia. Gastroenterology, 2001, 120, A237-A237.	0.6	3
236	Is a Fundamental Design Change for Gastrointestinal Endoscopes Required?. Journal of Clinical Gastroenterology, 2021, 55, 21-24.	1.1	3
237	Immune Activation in Functional Gastrointestinal Disorders. Gastroenterology and Hepatology, 2019, 15, 539-548.	0.2	3
238	Small intestinal bacterial overgrowth in inflammatory bowel disease. Indian Journal of Gastroenterology, 2022, 41, 23-29.	0.7	3
239	Evidence-Based and Emerging Diet Recommendations for Small Bowel Disorders. American Journal of Gastroenterology, 2022, 117, 958-964.	0.2	3
240	Letter: nonâ€invasive transabdominal stimulation device for the treatment of chronic constipation—proofâ€ofâ€principle study in adults. Alimentary Pharmacology and Therapeutics, 2022, 55, 1354-1356.	1.9	3
241	Genetics, H. pylori and the development of functional gastrointestinal disorders: A twin study. Gastroenterology, 2003, 124, A391.	0.6	2
242	Susceptibility genes and functional gastrointestinal disorders. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1792-1793.	1.4	2
243	Approach to the Patient with Dyspepsia and Related Functional Gastrointestinal Complaints., 0,, 38-61.		2
244	P172 - In what proportion of IBD patients coming to resection surgery was there an opportunity to optimise preoperative care? A one year audit of a tertiary referral hospital. Journal of Crohn's and Colitis, 2009, 3, S79.	0.6	2
245	Serotoninergic and non-serotoninergic effects of two tricyclic antidepressants on visceral nociception in a rat model. Scandinavian Journal of Gastroenterology, 2009, 44, 680-686.	0.6	2
246	Opportunities of twin research in gastroenterology. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 325-326.	8.2	2
247	Induction of Meal-related Symptoms as a Novel Mechanism of Action of the Duodenal-Jejunal Bypass Sleeve. Journal of Clinical Gastroenterology, 2020, 54, 528-535.	1.1	2
248	Routine assessment of gastrointestinal symptom using a validated questionnaire in the clinical setting to assess the probability of organic or functional gastrointestinal diseases. Neurogastroenterology and Motility, 2021, 33, e14091.	1.6	2
249	Draft Genome Sequence of Streptococcus salivarius AGIRA0003, Isolated from Functional Gastrointestinal Disorder Duodenal Tissue. Microbiology Resource Announcements, 2021, 10, e0075821.	0.3	2
250	Itopride in the Treatment of Functional Dyspepsia in Chinese Patients. Clinical Drug Investigation, 2011, , $1. $	1.1	2
251	The role of mood state and emotion regulation in the discrepancy between gastrointestinal symptom burden recorded prospectively and via recall questionnaire. Neurogastroenterology and Motility, 2021, , e14304.	1.6	2
252	Understanding GERD symptoms in the clinical setting. Drugs of Today, 2005, 41 Suppl B, 13-7.	0.7	2

#	Article	IF	CITATIONS
253	The effect of a new synthetic cholinergic compound (Aclatonium Napadisilate) on interdigestive motility and pancreatic function in humans. International Journal of Gastrointestinal Cancer, 1989, 5, 273-279.	0.4	1
254	Differential involvement of spinal NMDA, CGRP and NK1 receptors in responses to phasic vs. tonic colorectal distension. Gastroenterology, 2000, 118, A380.	0.6	1
255	Diurnal variation of abdominal motor responses to colorectal distension in a rat model. Gastroenterology, 2000, 118, A135.	0.6	1
256	Effects of a fixed peppermint oil caraway oil combination (PCC) on symptoms and quality of life in functional dyspepsia. Gastroenterology, 2001, 120, A237.	0.6	1
257	(Post) inflammatory visceral hyperalgesia: Don't we believe what we don't see?. Gastroenterology, 2002, 122, 823-825.	0.6	1
258	530 Complicated and Uncomplicated Peptic Ulcer Disease: the Altered Symptom Response to the Nutrient Challenge Is Linked to Gastric Motor Function. Gastroenterology, 2008, 134, A-75.	0.6	1
259	Are All Symptoms in Patients in IBD Due to Occult Inflammation?. American Journal of Gastroenterology, 2010, 105, 2703.	0.2	1
260	Sul 015 The Validity of a New Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for Use in the Clinical Setting. Gastroenterology, 2016, 150, S444.	0.6	1
261	Mo1629 Managing Functional Dyspepsia and IBS: Overlap Is Frequently Unrecognised in Clinical Practice, But Overlap Cases Are More Severely Impacted. Gastroenterology, 2016, 150, S735-S736.	0.6	1
262	Su1562 In Patients With Crohn's Disease Functional MRI Reveals an Alteration of Amygdala Function Induced by Anti-TNFa That Is Associated With Positive Self-attribution Biases and Reduced Symptom Response to a Standardised Nutrient Challenge. Gastroenterology, 2016, 150, S526-S527.	0.6	1
263	An in vitro and clinical dose-finding study of antifoaming effects of simethicone during colonoscopy. Indian Journal of Gastroenterology, 2019, 38, 268-272.	0.7	1
264	Mo1582 IS THERE AN ASSOCIATION BETWEEN IMPROVEMENT OF GI SYMPTOMS IN PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS AND ALTERATIONS OF CIRCULATING GUT HOMING T CELLS AND PRO-INFLAMMATORY CYTOKINES IN RESPONSE TO A 12 WEEK MULTIDISCIPLINARY INTERVENTION?. Gastroenterology, 2020, 158, S-904-S-905.	0.6	1
265	Su1204 VARIATIONS OF THE MUCOSA ASSOCIATED MICROBIOTA ALONG THE HUMAN GASTROINTESTINAL TRACT IN HEALTH AND INFLAMMATORY BOWEL DISEASE. Gastroenterology, 2020, 158, S-542.	0.6	1
266	Letter to the Editor: Oral Vancomycin Versus No Therapy for Pediatric Primary Sclerosing Cholangitis. Hepatology, 2021, 74, 1716-1717.	3.6	1
267	Clusters of community-dwelling individuals empirically derived from stool diaries correspond with clinically meaningful outcomes. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	0.8	1
268	Anti-TNFA Treatment in Crohn's Disease Reduced GI Symptoms and Alters Motivational Circuitry in the Brain. Gastroenterology, 2017, 152, S924.	0.6	1
269	Mo1544 IS SMALL INTESTINAL DYSBIOSIS (SIBO) RELATED TO IMPROVEMENT OF EPIGASTRIC PAIN, EARLY SATIETY AND POSTPRANDIAL PAIN IN RESPONSE TO ANTIMICROBIAL THERAPY WITH RIFAXIMIN IN PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS?. Gastroenterology, 2020, 158, S-889.	0.6	1
270	Opiodergic antinociceptive pathways modulate gastric mechanosensory function in healthy subjects. Gastroenterology, 2001, 120, A81-A81.	0.6	1

#	Article	IF	Citations
271	Funktionelle Dyspepsie und Reizdarmsyndrom. , 2005, , 435-447.		1
272	Zhizhu Kuanzhong Capsule in treating patients with functional dyspepsia postprandial distress syndrome: study protocol for a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. Trials, 2022, 23, .	0.7	1
273	Persistently Altered Visceral Perception after Resection of an Esophageal Granular Cell Myoblastoma: A Therapeutic Concept Revisited. Zeitschrift Fur Gastroenterologie, 2003, 41, 917-920.	0.2	0
274	GERD. Journal of Clinical Gastroenterology, 2007, 41, S204-S208.	1.1	0
275	Kolondivertikulose, Divertikulitis und Divertikelblutung. DoctorConsult - the Journal Wissen Fur Klinik Und Praxis, 2010, 1, e151-e155.	0.0	0
276	Letter: inverse correlation between <i>Helicobacter pylori</i> and obesity - a conclusion too early? Authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 40, 1120-1120.	1.9	0
277	Irritable bowel syndrome, dyspepsia and other chronic disorders of gastrointestinal function. Medical Journal of Australia, 2016, 205, 303-304.	0.8	0
278	Editorial: the burden of chronic liver disease – an ecological method sees the wood for the trees. Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 532-533.	1.9	0
279	Letter: investigating the intestinal mucosaâ€associated microbiota – relevance and potential pitfalls. Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 648-649.	1.9	0
280	6. Konzepte der Arzneimitteltherapie. , 2017, , 229-272.		0
281	Life in the small intestine: the forgotten microbiome?. Microbiology Australia, 2017, 38, 116.	0.1	0
282	Translating our microbiome into medicine. Medical Journal of Australia, 2017, 206, 287-288.	0.8	0
283	From trash to gold: gastrointestinal microbiome research in patients with functional gastrointestinal disorders. Journal of Investigative Medicine, 2021, 69, 793-795.	0.7	0
284	Dyspepsia: Treatment Options Directed to Specific Targets. Current Treatment Options in Gastroenterology, 2021, 19, 434-442.	0.3	0
285	Electroencephalographic evidence of unconscious and conscious attentional bias in people with functional gastrointestinal disorders: A pilot study. International Journal of Psychophysiology, 2021, 170, 30-42.	0.5	0
286	Funktionelle Dyspepsie (funktionelle Magenbeschwerden). , 2015, , 1-4.		0
287	Seroreactivity to Microbial Antigens and Gutâ€Homing Immune Responses in Functional Dyspepsia Patients with Postprandial Distress Syndrome. FASEB Journal, 2018, 32, 613.3.	0.2	0
288	Telenzepine, a new M1-receptor antagonist, is a more potent inhibitor of pentagastrin-stimulated gastric acid output than pirenzepine in dogs. Scandinavian Journal of Gastroenterology, 1990, 25, 293-7.	0.6	0